Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP

BACKGROUND: Cisplatin is the standard first‐line chemotherapeutic agent for the treatment of non‐small cell lung cancer (NSCLC). However, resistance to chemotherapy has been a major obstacle in the management of NSCLC. Aldehyde dehydrogenase 1A1 (ALDH1A1) overexpression has been observed in a variet...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yunyan, Wu, Shuangshuang, Xu, Wei, Liang, Yan, Li, Yue, Zhao, Weihong, Wu, Jianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217899/
https://www.ncbi.nlm.nih.gov/pubmed/27813328
http://dx.doi.org/10.1111/1759-7714.12400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217899/
https://www.ncbi.nlm.nih.gov/pubmed/27813328
http://dx.doi.org/10.1111/1759-7714.12400

Ejemplares similares